Merck
  • Home
  • Search Results
  • Abnormal Wnt signaling and overexpression of ABCG2 contributes to drug efflux properties of side population cells in nasopharyngeal carcinoma.

Abnormal Wnt signaling and overexpression of ABCG2 contributes to drug efflux properties of side population cells in nasopharyngeal carcinoma.

Molecular medicine reports (2015-06-18)
Guo-Fang Guan, De-Jun Zhang, Ying Zheng, Lian-Ji Wen, Duo-Jiao Yu, Yan-Qing Lu, Yan Zhao
ABSTRACT

The presence of cancer stem cells (CSCs) has major implications in the choice of cancer treatment strategy and is responsible for tumor relapse. CSCs have been isolated and characterized in several types of cancer; however, studies concerning the CSCs from nasopharyngeal carcinoma (NPC) are limited. Thus, the present study was designed to isolate and characterize the cancer stem-like side population (SP) cells from NPC samples. The fluorescence-activated cell sorting (FACS)-based Hoechst 33342 dye exclusion technique identified that 3.9% of cells from NPC samples were cancer stem-like SP cells. Upon treatment with verapamil (ABC transporter inhibitor), the percentage of SP cells was significantly reduced to 0.7%, which confirms that the ABC transporter protein exhibits a significant role in drug exclusion. Fluorescence microscopy analysis revealed that the FACS purified SP cells showed increased expression of ABCG2 (ATP transporter protein), Oct-4 and CD44 (stem cell surface protein). Furthermore, these SP cells exhibited increased mRNA expression of ABCG2 and anti-apoptotic factor Bmi-1, which contribute to multi-drug resistance and increased cell survival rate. Notably, the Wnt/β-catenin signaling pathways are altered in SP cells. In addition, using reverse transcription‑quantitative polymerase chain reaction analysis it was observed that the cells exhibited increased expression of DKK1 and AXIN2. In conclusion, data from the present study clearly demonstrated that the presence of cancer stem-like SP cells from NPC may be responsible for chemotherapeutic drug resistance, tumor recurrence and invasion.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
FGF-2 human, recombinant, expressed in insect cells, ≥85% (SDS-PAGE)
Sigma-Aldrich
FGF-2 human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
Sigma-Aldrich
Fgf-2 from rat, recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)
Sigma-Aldrich
Anti-CD44 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
Fluorescein 5(6)-isothiocyanate, ≥90% (HPLC)
Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Sigma-Aldrich
Monoclonal Anti-POU5F1 (Oct4) antibody produced in mouse, ~1.0 mg/mL, clone PF-29, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Propidium iodide solution, solution (1.0 mg/ml in water)
Bright-Line Hemacytometer, supplied with two cover slips
Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder
Sigma-Aldrich
Fluorescein isothiocyanate isomer I, ≥97.5% (HPLC)
Sigma-Aldrich
Fgf-2 from mouse, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)